Moving fecal microbiota transplantation into the mainstream

Robert Orenstein, Cheryl L. Griesbach, John K. Dibaise

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.

Original languageEnglish (US)
Pages (from-to)589-598
Number of pages10
JournalNutrition in Clinical Practice
Issue number5
StatePublished - Oct 2013


  • Clostridium difficile metagenome
  • fecal microbiota transplant
  • fecal transplant
  • microbiome

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics


Dive into the research topics of 'Moving fecal microbiota transplantation into the mainstream'. Together they form a unique fingerprint.

Cite this